In last trading session, Immuneering Corp (NASDAQ:IMRX) saw 0.4 million shares changing hands with its beta currently measuring -0.33. Company’s recent per share price level of $2.09 trading at -$0.04 or -1.88% at ring of the bell on the day assigns it a market valuation of $64.90M. That closing price of IMRX’s stock is at a discount of -325.36% from its 52-week high price of $8.89 and is indicating a premium of 52.15% from its 52-week low price of $1.00. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.41 million shares which gives us an average trading volume of 5.45 million if we extend that period to 3-months.
For Immuneering Corp (IMRX), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.67. Splitting up the data highlights that, out of 3 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 3 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.39 in the current quarter.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Immuneering Corp (NASDAQ:IMRX) trade information
Upright in the red during last session for losing -1.88%, in the last five days IMRX remained trading in the red while hitting it’s week-highest on Friday, 11/22/24 when the stock touched $2.09 price level, adding 7.11% to its value on the day. Immuneering Corp’s shares saw a change of -71.56% in year-to-date performance and have moved -0.95% in past 5-day. Immuneering Corp (NASDAQ:IMRX) showed a performance of 8.85% in past 30-days. Number of shares sold short was 2.05 million shares which calculate 1.19 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 13 to the stock, which implies a rise of 83.92% to its current value. Analysts have been projecting 3 as a low price target for the stock while placing it at a high target of 41. It follows that stock’s current price would drop -43.54% in reaching the projected high whereas dropping to the targeted low would mean a loss of -43.54% for stock’s current value.
Immuneering Corp (IMRX) estimates and forecasts
Statistics highlight that Immuneering Corp is scoring comparatively lower than the scores of other players of the relevant industry. The company added 50.36% of value to its shares in past 6 months, showing an annual growth rate of 1.06% while that of industry is 17.70. Apart from that, the company came raising its revenue forecast for fiscal year 2024.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -57.97% during past 5 years.
Immuneering Corp (NASDAQ:IMRX)’s Major holders
Insiders are in possession of 29.12% of company’s total shares while institution are holding 30.11 percent of that, with stock having share float percentage of 42.48%. Investors also watch the number of corporate investors in a company very closely, which is 30.11% institutions for Immuneering Corp that are currently holding shares of the company. CITADEL ADVISORS LLC is the top institutional holder at IMRX for having 1.88 million shares of worth $2.41 million. And as of 2024-06-30, it was holding 6.4083 of the company’s outstanding shares.
The second largest institutional holder is VANGUARD GROUP INC, which was holding about 1.07 million shares on 2024-06-30. The number of shares represents firm’s hold over 3.6442 of outstanding shares, having a total worth of $1.37 million.
On the other hand, Vanguard Total Stock Market Index Fund and Price (T.Rowe) Health Sciences Fund are the top two Mutual Funds which own company’s shares. As of Jun 30, 2024 , the former fund manager was holding 736.19 shares of worth $1.54 million or 2.37% of the total outstanding shares. The later fund manager was in possession of 558.38 shares on Jun 30, 2024 , making its stake of worth around $1.17 million in the company or a holder of 1.80% of company’s stock.
